Meet the team that lives life science to support your growth and success.

Andrew is a radiopharmaceutical industry executive with extensive commercial strategy and leadership experience spanning the continuum of both the clinical and the commercial sides of the diagnostic and therapeutic radiopharmaceutical, molecular imaging, and general nuclear medicine businesses.  His broad experience includes executive and senior executive positions at Cardinal Health, Lantheus, and the Lehigh Valley Health Network providing him more than 30 years of expertise in creating and implementing strategies introducing new radiopharmaceuticals and technological innovations which produce results in the marketplace, including the launch and commercialization of multiple industry-leading SPECT, PET, Radiopharmaceutical Therapy and Theranostic products.
From raw material sourcing to the patient bedside, Andrew excels at applying 30+ years of industry-specific lessons learned to providing strategic solutions for successfully navigating the complexity of the radiopharmaceutical business.  

Deepak Behera is a highly accomplished physician-scientist and strategist with over two decades of leadership experience in the medical, academic, and pharmaceutical sectors. His proficiency in medical affairs, clinical development, and radiopharmaceuticals, has been pivotal to the successful launch and commercialization of two industry-leading products.

His early clinical experience grounded him in practical insights before transitioning to academic translational research at Stanford University. His work at Stanford led to birth of two startups, five early-phase trials, and the co-authorship of two patents, highlighting his innovative approach to nuclear medicine.

Deepak’s transition to the pharmaceutical industry was marked by his impactful roles as Senior Medical Director, Head of Medical Affairs, Strategic Medical Director, and Chief Medical Officer. These positions saw him navigate complex clinical development landscapes, Phase I-III study designs, FDA interactions, and oversee the successful launch of two commercial products. Having worked collaboratively with American, European and Asian companies, Deepak is culturally sensitive and adaptable in a global medical landscape.

As a scholar, Deepak has enriched the medical discourse with over 20 peer-reviewed articles and 15 impactful lectures and presentations. His dedication to the medical community extends beyond his professional roles, as demonstrated by his active involvement in organizations like Adaptive Research, EPPIC Global, IASNM, and MISI. As an industry pioneer, Deepak’s embodies the seamless blend of medical expertise, innovative research, commercial understanding and strategic leadership in medical affairs and radiopharmaceuticals.

Jon is an entrepreneurial-minded scientist with over 20 years of research and development experience in the pharma and biotech industry (spanning GSK, Eli Lilly and SynOA Therapeutics). While at GSK he was focused on osteoarthritis therapeutic development through leading and shaping corporate strategy and employing both biologics and small molecule-based approaches to discover and progress clinical candidates. At GSK, Jon’s lab discovered and progressed two molecules to the candidate selection milestone. Thereafter, he led the clinical development effort as Early Development Leader providing experience in drafting protocols and informed consents, investigator brochures as well as regulatory IND submissions and application of Good Clinical Practice guidelines. Jon received his PhD in Pathology and Cell Biology from Thomas Jefferson University where he studied hepatitis B virus immunopathology and the effects of antiviral drug treatment and alcohol consumption on viral replication and gene expression in a novel HBV SCID mouse model he developed.

With over forty years of experience in oncology and nuclear medicine, Dr. McEwan is a world-renowned expert in his field. Most recently, he was Chief Medical Officer at Ariceum, a company developing novel medicines for systemic targeted radiotherapy (SRT), and immediately prior to that he was Vice President of Radiopharmaceuticals at Ipsen. As an academic physician, Dr. McEwan served as Chair of the Departments of Radiology and Oncology at the University of Alberta. Dr. McEwan has worked as a physician at Alberta Health Services for over thirty years, with additional postings that have included Clinical Director of the Cross Cancer Institute and Clinical Head of Diagnostic Imaging at the University of Alberta Hospital. Dr. McEwan has authored over 120 publications in oncology and radiopharmaceuticals and SRT.

Victor recently served as Chief Medical Officer for 3M where he led efforts in Health Care Compliance and the integration of Medical/Clinical inputs into the product development process. He has also been a thought leader for the Frost & Sullivan Mind X-change and Q1 Productions. Victor also has experience in medical device development, medical and clinical affairs, health economics, reimbursement, post marketing studies, osteoporosis, in vitro diagnostics (IVD), cardiac electrophysiology, ophthalmology, diabetes, and head trauma.  

Wil worked for over 35 years in clinical imaging as a Professor of Radiology, initially at the Mallinckrodt Institute in St Louis and then Temple University in Philadelphia before switching to industry and spending 5 years as a Medical Director of Icon Medical Imaging. He received an MBA from Washington University, Olin School of Business in 2000.  He has expertise and has published extensively in medical imaging, the development of magnetic resonance imaging (MRI) techniques and optimization of other imaging modalities to improve understanding of disease processes such as traumatic brain injury, stroke, and musculoskeletal disorders. As a practicing physician, Wil has been involved with clinical trials both from the clinical and the CRO sides with a specific focus on imaging endpoints. 

Ina Margaretha is based in Amsterdam and has a 25 years of experience with the fields of clinical drug development, strategic partnerships, business development, and building innovative biotech businesses and CROs in Europe.

Ina Margaretha has been developing business plans for start-ups, organizing funding (including European grants), leading R&D programs, outsourcing development and commercial strategies to develop groundbreaking therapies in the field of immunology, allergy, inflammatory diseases (including post-COVID), musculoskeletal, orphan diseases and CNS, ultimately negotiating attractive licensing deals to accelerate time to market. She has also experience in gene and cell therapies and combined medical devices.

Over the course of her career, she has created strong relationships with life science investors, built strong scientific and operational teams, and developed long term partnerships with biopharma partners to bring innovative treatments to patients.

Ina Margaretha has a Master’s Degree in Biomedical Sciences from the Leiden University Medical Centre, The Netherlands.

Marybeth is a highly experienced results-oriented marketing executive with a strong track record of team building, strategic planning and tactical execution in fast-paced organizations. Marybeth serves as an account strategist and fractional Chief Marketing Officer to support digital innovation, B2B marketing, product marketing, partner marketing and content strategy for life sciences technology and digital health organizations. With her demonstrated history in Executive Leadership, Business Development, Sales Growth, and Marketing, Marybeth excels at quickly addressing root cause issues by applying analytical problem solving and optimize marketing aligning with business strategy to accelerate innovation and growth.

Andrew (Andy) brings more than 40 years’ experience in the biotech/pharmaceutical industry having initiated and built several biotech companies including Inotek Pharmaceuticals Corporation, Radikal Therapeutics, Salzman Group, Chilmark Laboratories, and Orphan Technologies, where he oversaw the entire spectrum of drug development activities, including discovery chemistry, pharmacology, and preclinical activities, manufacturing, clinical Phase I-II, as well as the US and international regulatory strategies. Andy has over 170 peer-reviewed articles, 47 patents, and was the inventor and development lead for the clinical-stage PARP-1 inhibitor. More recently Andy’s focus and interest has been on the clinical use of cannabinoids.

Rosemary has extensive sales and marketing experience in Medical Imaging, Software, Drug Development, Medical Devices, Oncology, Neuromuscular, Musculoskeletal and Metabolic diseases. With her demonstrated history in Executive Leadership, Business Development, Sales Growth, and Marketing in the medical device and pharmaceutical development industries, Rosemary excels at preparing and delivering presentations to investors as well as Board of Director members.  

As a results-oriented executive, Nick has a strong track record of success in team building, strategic planning, and tactical execution in pharma, biotech, and medical device organizations. Previously Nick’s extensive experience includes senior executive positions at Merck, Merial and Reliefband providing him expertise with global drug, dietary supplements, nutraceuticals, biologicals, and med device development and commercialization experience. He is a serial entrepreneur taking companies from start up through financing stages to exit. Nick was the founder, Chairman, and CEO of Topaz Pharmaceuticals, the founder and managing partner of Humanitas Consulting, the co-founder of Reliefband Technologies, a med device company as well as co-founder of BioVeras – bringing blockchain to life sciences. In addition, Nick has served for 10 years as an Adjunct Professor at the University of the Sciences, Philadelphia, specializing in pharmaceutical, biotech and med device entrepreneurship, marketing, and commercialization as well as direct involvement with the PA Biotechnology Center, Doylestown, since 2005.

A recognized expert with more than twenty years of experience with clinical imaging and clinical trial design. Experience includes 10 years at Pfizer developing and implementing imaging biomarkers in clinical studies across therapeutic areas. Formerly Vice President of Imaging and Clinical Development at ImaginAb, responsible for the development and clinical testing of novel PET tracers. Working with medical device and biotech companies to implement novel biomarkers and design studies to drive go/no-go development decisions.